A H Wang1, X Y Tian, J J Yu, J Q Mi, H Liu, R F Wang. 1. Department of Obstetrics and Gynaecology, First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.
Abstract
OBJECTIVE: The effects of celecoxib, a selective cyclo-oxygenase-2 (COX-2) inhibitor, on HeLa cervical cancer cell growth and radiosensitivity were investigated. METHODS: Cytotoxicity was quantified using a 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyltetrazolium assay and effects on radiosensitivity were assessed using the lethal dose, quasithreshold dose, fraction surviving after 2 Gy irradiation and the radiosensitization ratio (SER, based on average lethal dose) determined using a single-hit multitarget model. RESULTS: Celecoxib inhibited HeLa cell proliferation in a concentration- and time-dependent manner, with a half-maximal inhibitory concentration at 72 h of 44 μmol/l. Treatment with 20 μmol/l celecoxib for 72 h before irradiation was associated with an SER of 2.01. The SER of irradiated cells was 2.41 when treated with 40 μmol/l celecoxib before irradiation, 1.89 when treated simultaneously and 1.44 when treated after irradiation. Celecoxib downregulated COX-2 and vascular endothelial growth factor C (VEGF-C) expression evaluated immunohistochemically. CONCLUSION: Celecoxib pretreatment radiosensitizes HeLa cells via a mechanism dependent on down-regulation of COX-2 and VEGF-C.
OBJECTIVE: The effects of celecoxib, a selective cyclo-oxygenase-2 (COX-2) inhibitor, on HeLa cervical cancer cell growth and radiosensitivity were investigated. METHODS:Cytotoxicity was quantified using a 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyltetrazolium assay and effects on radiosensitivity were assessed using the lethal dose, quasithreshold dose, fraction surviving after 2 Gy irradiation and the radiosensitization ratio (SER, based on average lethal dose) determined using a single-hit multitarget model. RESULTS:Celecoxib inhibited HeLa cell proliferation in a concentration- and time-dependent manner, with a half-maximal inhibitory concentration at 72 h of 44 μmol/l. Treatment with 20 μmol/l celecoxib for 72 h before irradiation was associated with an SER of 2.01. The SER of irradiated cells was 2.41 when treated with 40 μmol/l celecoxib before irradiation, 1.89 when treated simultaneously and 1.44 when treated after irradiation. Celecoxib downregulated COX-2 and vascular endothelial growth factor C (VEGF-C) expression evaluated immunohistochemically. CONCLUSION:Celecoxib pretreatment radiosensitizes HeLa cells via a mechanism dependent on down-regulation of COX-2 and VEGF-C.
Authors: Alejandro D Soriano-Hernandez; Daniela Madrigal-Pérez; Hector R Galvan-Salazar; Margarita L Martinez-Fierro; Laura L Valdez-Velazquez; Francisco Espinoza-Gómez; Oscar F Vazquez-Vuelvas; Bertha A Olmedo-Buenrostro; Jose Guzman-Esquivel; Iram P Rodriguez-Sanchez; Agustin Lara-Esqueda; Daniel A Montes-Galindo; Ivan Delgado-Enciso Journal: Oncol Lett Date: 2015-08-07 Impact factor: 2.967
Authors: Soo Young Jeong; Joon-Yong Chung; Sun-Ju Byeon; Chul Jung Kim; Yoo-Young Lee; Tae-Joong Kim; Jeong-Won Lee; Byoung-Gie Kim; Ye Lin Chae; So Young Oh; Chel Hun Choi Journal: Front Oncol Date: 2021-07-19 Impact factor: 6.244